Investment Analysts’ Recent Ratings Changes for Thermo Fisher Scientific (TMO)

Several brokerages have updated their recommendations and price targets on shares of Thermo Fisher Scientific (NYSE: TMO) in the last few weeks:

  • 2/2/2018 – Thermo Fisher Scientific was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 2/1/2018 – Thermo Fisher Scientific had its price target raised by analysts at Bank of America Corp from $235.00 to $250.00. They now have a “buy” rating on the stock.
  • 2/1/2018 – Thermo Fisher Scientific had its price target raised by analysts at Morgan Stanley from $223.00 to $227.00. They now have an “overweight” rating on the stock.
  • 2/1/2018 – Thermo Fisher Scientific had its price target raised by analysts at Barclays PLC from $225.00 to $245.00. They now have an “overweight” rating on the stock.
  • 2/1/2018 – Thermo Fisher Scientific had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $239.00 price target on the stock, up previously from $200.00. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 1/20/2018 – Thermo Fisher Scientific was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Post a promising third-quarter 2017 performance we are encouraged by Thermo Fisher’s series of product launches along with progress in precision medicine initiatives. At the same time, we are upbeat about Thermo Fisher recently completing the acquisition of Phenom-World. Moreover, the newly-integrated FEI Company has already started to boost its analytical instruments arm. We are currently looking forward to Thermo Fisher gaining entry into the CDMO market through the recently-closed $7.2 billion acquisition of Patheon. The raised guidance is all the more impressive and indicative of this overall bullish trend to continue through 2017. Unfavorable macroeconomic conditions continue to weigh heavily on Thermo Fisher's stocks. Over the past six months, Thermo Fisher is trading above the broader industry. On the flip side, competitive headwinds and rising operating costs continue to pose a threat on the stock's value.”
  • 1/11/2018 – Thermo Fisher Scientific was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Post a promising third-quarter 2017 performance we are encouraged by Thermo Fisher’s series of product launches along with progress in precision medicine initiatives. At the same time, we are upbeat about Thermo Fisher recently completing the acquisition of Phenom-World. Moreover, the newly-integrated FEI Company has already started to boost its analytical instruments arm. We are currently looking forward to Thermo Fisher gaining entry into the CDMO market through the recently-closed $7.2 billion acquisition of Patheon. The raised guidance is all the more impressive and indicative of this overall bullish trend to continue through 2017. Unfavorable macroeconomic conditions continue to weigh heavily on Thermo Fisher's stocks. Over the past six months, Thermo Fisher is trading above the broader industry. On the flip side, competitive headwinds and rising operating costs continue to pose a threat on the stock's value.”
  • 1/5/2018 – Thermo Fisher Scientific is now covered by analysts at BTIG Research. They set a “buy” rating and a $230.00 price target on the stock.
  • 1/3/2018 – Thermo Fisher Scientific is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $220.00 price target on the stock.

Shares of Thermo Fisher Scientific Inc. (TMO) traded up $3.60 during mid-day trading on Monday, hitting $203.78. 654,692 shares of the stock traded hands, compared to its average volume of 1,679,239. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.92 and a current ratio of 1.35. The firm has a market cap of $80,271.26, a PE ratio of 36.39, a price-to-earnings-growth ratio of 1.47 and a beta of 1.11. Thermo Fisher Scientific Inc. has a 1 year low of $151.74 and a 1 year high of $226.44.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, January 31st. The medical research company reported $2.79 earnings per share for the quarter, beating the consensus estimate of $2.66 by $0.13. Thermo Fisher Scientific had a net margin of 10.64% and a return on equity of 16.01%. The firm had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $5.72 billion. During the same quarter in the previous year, the company posted $2.41 EPS. The company’s revenue was up 22.1% compared to the same quarter last year. analysts expect that Thermo Fisher Scientific Inc. will post 10.81 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, April 16th. Shareholders of record on Thursday, March 15th will be given a $0.17 dividend. The ex-dividend date is Wednesday, March 14th. This represents a $0.68 dividend on an annualized basis and a yield of 0.33%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. Thermo Fisher Scientific’s dividend payout ratio is presently 10.71%.

In other Thermo Fisher Scientific news, SVP Gregory J. Herrema sold 33,327 shares of the company’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $219.70, for a total value of $7,321,941.90. Following the transaction, the senior vice president now owns 60,471 shares of the company’s stock, valued at $13,285,478.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Patrick M. Durbin sold 6,000 shares of the company’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $217.55, for a total transaction of $1,305,300.00. The disclosure for this sale can be found here. Insiders sold 144,327 shares of company stock worth $28,680,042 in the last ninety days. 0.49% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply